Skip to main content
HYPD
NASDAQ Life Sciences

Hyperion DeFi Reports FY25 Net Loss Double Expectations; Q4 Adjusted Gross Profit Up 87%

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$3.51
Mkt Cap
$30.239M
52W Low
$0.85
52W High
$17.18
Market data snapshot near publication time

summarizeSummary

Hyperion DeFi reported a significantly wider net loss for fiscal year 2025 than anticipated, despite showing strong quarter-over-quarter growth in its non-GAAP Adjusted Gross Profit and providing positive 2026 guidance for this metric.


check_boxKey Events

  • Significant FY25 Net Loss Reported

    The company reported a net loss of ($45.3 million) for fiscal year 2025, or ($9.40) per share, which is substantially wider than the ($4.62) per share loss anticipated by Reuters.

  • Strong Q4'25 Adjusted Gross Profit Growth

    Adjusted Gross Profit (non-GAAP) increased by 87% quarter-over-quarter, from $439 thousand in Q3'25 to $821 thousand in Q4'25.

  • Positive 2026 Adjusted Gross Profit Guidance

    Management anticipates $4 million to $6 million in Adjusted Gross Profit for 2026, representing approximately a 4x increase over FY25 results.

  • Bylaw Amendments Approved

    The Board of Directors approved Third Amended and Restated Bylaws, reducing the quorum requirement for stockholder meetings to one-third of shares and enabling stockholder action by written consent.


auto_awesomeAnalysis

Hyperion DeFi, Inc. reported a significantly wider net loss for fiscal year 2025, with a loss of $9.40 per share, which is more than double the $4.62 per share loss anticipated by Reuters just two days prior. This substantial miss on the bottom line is a critical negative signal, especially for a company with a market capitalization of approximately $30 million, as the annual net loss of $45.3 million far exceeds its market value. While the company demonstrated strong operational growth, with Adjusted Gross Profit increasing by 87% quarter-over-quarter in Q4 2025 and providing positive 2026 guidance, the GAAP losses remain a significant concern. The successful capital raises of $91.0 million in FY25 were crucial for liquidity but also highlight the substantial capital requirements and prior dilution. Additionally, the company amended its bylaws to reduce the quorum for stockholder meetings, which could streamline governance but also potentially reduce broader shareholder influence.

At the time of this filing, HYPD was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2M. The 52-week trading range was $0.85 to $17.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HYPD - Latest Insights

HYPD
Apr 17, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
8
HYPD
Mar 27, 2026, 5:54 PM EDT
Filing Type: 10-K
Importance Score:
9
HYPD
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
HYPD
Mar 24, 2026, 8:53 AM EDT
Source: Reuters
Importance Score:
7
HYPD
Jan 09, 2026, 4:30 PM EST
Filing Type: 424B3
Importance Score:
9
HYPD
Jan 05, 2026, 8:00 AM EST
Filing Type: 4
Importance Score:
8
HYPD
Jan 05, 2026, 5:31 PM EST
Filing Type: 8-K
Importance Score:
8